Earnings call
Advanced Enzyme Technologies Q1 FY27 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company expects 8-10% growth in its U.S. business, citing geopolitical issues as a reason for steady U.S. numbers; it expects growth of about 8% by the end of the year. Revenue was INR 1,898 million in Q1 FY '27, up 2% YoY and down 7% compared to the previous quarter. The company has 15-20 molecules under development in its pipeline, with a few coming through every quarter. Board approved a buyback of INR 697 million at a ceiling price of INR 500 per share via the open market route.
The numbers management gave
Results
- Revenue was INR 1,898 million in Q1 FY '27, up 2% YoY and down 7% compared to the previous quarter.
Show source
Our top line for the quarter stood at INR 1,898 million, registering a 2% YoY growth.
- The company recorded an additional sales reversal of INR 100 million in Q1 FY '27, over and above the revenue reversals generally accounted for every quarter under its revenue-recognition practices.
Show source
On account of revenue recognition accounting principles, this quarter was impacted by an additional sales reversal amounting to INR 100 million over and above reversal of revenue ge nerally being accounted in every quarter.
- EBITDA was INR 510 million in Q1 FY '27, down 10% YoY and 19% QoQ.
Show source
Page 2 of 19 EBITDA for the quarter came in at INR 510 million, down 10% YoY and 19% QoQ.
- EBITDA margin was 27% in Q1 FY '27, compared with 30% in Q1 FY26 and 31% in Q4 FY26; consolidated margins moderated primarily because of lower top-line realization, elevated power and fuel costs driven by global energy disruption, and a temporary shift in sales mix.
Show source
Consequently, the EBITDA margin stood at 27% compared to 30% in Q1 FY26 and 31% in Q4 FY26.
- Profit after tax was INR 386 million in Q1 FY '27, down 5% YoY and 15% sequentially.
Show source
Moving to profitability, profit after tax stood at INR 386 million declining 5% YoY and 15% sequentially.
- PAT margin was 20% in Q1 FY '27, compared with 22% in both Q1 FY26 and Q4 FY26.
Show source
The PAT margin for the quarter was 20% compared to 22% in both Q1 FY26 and Q4 FY26.
Show 14 more statements
Results
- Human Healthcare revenue was INR 1,139 million in Q1 FY27, down 7% YoY and 11% sequentially, primarily due to lower sales in the Pharma API business; the segment contributed 60% of total revenue.
Show source
Let's begin with Human Healthcare: Revenues from Q1 FY27 stood at INR 1,139 million, reflecting a 7% YoY decline and 11% sequential decline.
- Bioprocessing revenue was INR 306 million in Q1 FY27, up 30% YoY and down 5% sequentially; the growth was driven by healthy growth in the Food business, and the segment contributed 16% of total revenues.
Show source
Turning to Bioprocessing, the segment reported revenues of INR 306 million, delivering 30% YoY growth.
- India sales in the Human Healthcare segment were about INR 580 million in Q1 FY27, compared with INR 699 million in Q4 and INR 659 million in Q1 of last year.
Show source
For Q1 FY27, our India sales is about INR 580 million as compared to INR 699 million in Q4 and INR 659 million in Q1 of last year.
- International sales in the Human Healthcare segment were INR 559 million in Q1 FY27, compared with INR 582 million in Q4 and INR 552 million in Q1 FY26.
Show source
International sales, INR 559 million as compared to INR 582 in Q4 and INR 552 in Q1 FY26.
- Human Healthcare segment revenue was about INR 1,139 million in Q1 FY27, compared with INR 1,281 million in Q4 and INR 1,221 million in Q1.
Show source
The total from this segment is about INR 1,139 million as compared to INR 1,281 million in the previous quarter of Q4, and Q1 was INR 1,221 million.
- The company spent about INR 90 million on R&D in Q1 FY27, compared with INR 86 million in Q1 FY26; R&D expenditure was about 4.75% in Q1 FY27 compared with 4.62% in Q1 FY26.
Show source
R&D expenditure, we have spent about INR 90 million in the Q1 of FY27 as compared to INR 86 million in Q1 of FY26.
- International sales were INR 559 million in Q1 FY27, compared with INR 582 million and INR 562 million.
Show source
International sales was INR 559 million as compared to INR 582 and INR 562 million.
- Biocatalysis revenue was INR 45 million in Q1 FY27, compared with INR 44 million in the last quarter of Q4.
Show source
Beni Prasad Rauka Biocatalysis number INR 45 million during this quarter as compared to INR 44 million in the last quarter of Q4.
- Advanced Enzymes Technologies Limited’s Specialized Manufacturing segment contributed 11% of total revenue and its revenue increased by 41% year-on-year to ₹200 million in Q1 FY27.
Show source
Lastly, Specialized Manufacturing reported revenues of INR 200 million, registering a robust 41% YoY growth and 11% increase over the previous quarter.
- The company observed an improvement in B2C revenue in USA in Q1 FY27.
Show source
We observed an improvement in our B2C revenue in USA.
Money and capital
- Board approved a buyback of INR 697 million at a ceiling price of INR 500 per share via the open market route.
Show source
We are pleased to announce that the Board has approved a buyback of INR 697 million at a ceiling price of INR 500 per share via open market route.
- ESOP scheme was for 25 lakhs, of which 11 lakhs shares had been granted in two different tranches; those shares will vest over five years.
Show source
ESOP scheme was for 25 lakhs, but so far, we have granted, I think, in two different tranches, 11 lakhs shares only.
- The company had inventory of about INR 190 crores, receivables of about INR 131 crores, payables of about INR 41 crores, and about INR 280 crores invested in working capital on 30th June 2026.
Show source
INR 280 crores was roughly invested in the working capital.
- Advanced Enzyme Technologies' working capital cycle is generally about 125-138 days.
Show source
In terms of number of days, generally our working capital cycle is about 125-138 days.
What it expects ahead
What management expects
- The company expects 8-10% growth in its U.S. business, citing geopolitical issues as a reason for steady U.S. numbers; it expects growth of about 8% by the end of the year.
Show source
Beni Prasad Rauka I think we have explained you that we are expecting 8-10% of growth in our U.S. business.
- The company expects EBITDA margins to return to about 30% of EBITDA for the rest of the year.
Show source
We expect that it shall come back to the normal level of about 30% of EBITDA.
- The company expects to have a 30-32% EBITDA margin and to increase its R&D pace to increase productivity.
Show source
But as of now, we will just like to continue that we will be having a 30-32% of EBITDA margin, and that is what we are saying.
- The company expects progressive momentum as the year advances, following a softer, more muted start to the fiscal year.
Show source
However, the fundamental strength of our business remains firmly intact, and we anticipate progressive momentum as the year advances.
- The company expects double-digit growth in the balance three quarters of the year.
Show source
As of now, we think we should be able to grow in double digits.
What it is building and selling
Segments
- The company has 15-20 molecules under development in its pipeline, with a few coming through every quarter.
Show source
We are always working on the new molecules, there are always 15-20 molecules under the pipeline, and few of them are always coming every quarter.
- About 70-80% of Advanced Enzyme Technologies' customers are generally constant, while 20-30% change.
Show source
Generally, like 70-80%, customers are always constant.
Everything else said on the call
Group structure
- The company announced the acquisition of the remaining 4.28% stake in its existing subsidiary JC Biotech for INR 79.79 million, resulting in a total stake of 100% and making JC Biotech a wholly-owned subsidiary.
Show source
The company has also announced the acquisition of the remaining stake of 4.28% for a consideration of INR 79.79 million in our existing subsidiary, JC Biotech, resulting in a total stake of 100%, making it wholly-owned subsidiary.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Lakshmi Narayanan Am I clear now? Or is it still a problem, sir?
Answer, beni prasad
Beni Prasad Rauka No. Still, there's a problem.
Question
Abhishek Navalgund Yeah.
Answer, beni prasad
Beni Prasad Rauka This is what we are going to spend.
Question
Abhishek Navalgund Yeah. I'm saying, this INR 123 crore will be entirely spent in FY27, and if that is the case, for which all projects, if you could highlight.
Answer, beni prasad
Beni Prasad Rauka I think out of this, about INR 20 crores will stretch to probably Q2 of FY27 also. Mainly, one of our subsidiaries, because we talk about the consolidated number.
Question
Abhishek Navalgund Sure. Basically, what I'm trying to understand is, out of this INR 123 crore, what could be the growth CapEx? If you keep aside the maintenance CapEx, what could be the growth CapEx that we'll be incurring in this year?
Answer, beni prasad
Beni Prasad Rauka Out of this, I think INR 20 crore is normal capital expenditure. INR 50 crores will go for R&D, which is already under work in progress. Maybe it will become functional in the next quarter or so. Balance is all about the growth only. R&D is not kind of immediate growth, but, of course, it is always for a sustained growth only.
Question
Abhishek Navalgund Okay. So, the remaining part, this is in the Human Nutrition side or which other segment, the growth CapEx?
Answer, beni prasad
Beni Prasad Rauka CapEx is not meant for any particular segment, as such because we manufacture enzymes for different industry.
Question
Abhishek Navalgund I'm saying this is like a step up as compared to last few years, and we always maintain that in terms of fermentation utilization is around 55-60%. Are we close to maybe 70%, and that's why you are doing this? Just wanted to understand the reason for this step up in CapEx.
Answer, mukund kabra
Mukund Kabra We are close to 70-75%, and we will take the call in the next quarter, and we may start some of the CapEx expenditure for increasing our capacity. Page 5 of 19 Abhishek Navalgund Sure.
Question
This is helpful. Next question is, basically, what is stopping us from growing strongly in the U.S. market? Because, I think, you just highlighted few International Human Nutrition numbers. In this quarter also, we have witnessed a decline of 14-odd percent. Could we please explain what is the reason behind this?
Answer, beni prasad
Beni Prasad Rauka I think overall, if you see the situation in the U.S., it's not so conducive as of now. What we are also doing is that we have been following a path where now we are trying to brand most of our products. You know, this tipping is taking some time. Because of that, if you see the numbers, it is kind of steady numbers, not getting any such significant increase in those numbers. Because the business is undergoing some kind of a changes. Again, you would agree that the kind of situation happening in USA is also not so conducive from business point of view. Couple of issues are there that is, again, being addressed by the company.
Answer, beni prasad
Because the geopolitical situation is something that also creates a lot of issues in managing the business.
Question
Abhishek Navalgund Okay. My last question is, what is the number for serratiopeptidase this quarter?
Answer, beni prasad
Beni Prasad Rauka I think we requested earlier also that we will stop sharing those numbers.
Question
Abhishek Navalgund Okay. No, because there was some ban kind of a thing which we saw in the news this quarter. Just wanted to understand, will there be any impact because of that, or we don't see any meaningful impact because of the F DC combination there?
Answer, mukund kabra
Mukund Kabra There will not be any meaningful impact. Maybe 1% here and there.
Question
Lakshmi Narayanan Sir, I was just looking at our U .S. business growth over a slightly longer period of 8, 9 years or even more. While the U.S. market per se has actually grown on the enzyme thing, I think broad numbers are around 6 or 7% of the industry level. Our growth has been divergent from that. Of course, there have been COVID in the middle. There have been logistics issues, and there's also been client cost issues, whi ch I understand. I'm just trying to understand broadly whether this divergence is more an internal issue or an external issue. How do we address this? Because we have good products. We have good patents, but still, we are unable to, at least, from the look s of it, sca
Answer, beni prasad
Beni Prasad Rauka Lakshmi Narayanan ji, challenges are several. I think in past, also, we have explained. Post COVID, things were going to stabilize. But then, last one and a half years, or rather one year, you can say, we have been facing this geopolitical situation. In addition to that, I think we have also explained, a couple of times that we are changing our business model in U.S. per se, basically looking into kind of branding most of the things. Most of the products which we are selling, most of the ingredients we are selling. Page 6 of 19 This process is taking some time to really consolidate the entire operations , entire customers.
Answer, beni prasad
This is one issu e besides the geopolitical si tuation, so everything is going in such a way that we don't see any kind of big numbers. Although in FY25, we have seen a kind of a 10% growth or so. FY26, again, it was kind of down. Now, again, because this is the first quarter we have to wait and watch. We see better visibility as we progress. All these issues are now being faced. As you mentioned, the market is big, but then you have to also carve out a niche segment for yourself.
Answer, beni prasad
Otherwise, this kind of, you want to become a commodity or not. That's not our exact business strategy. We are trying to, again, revamp and change our business model in such a way that at least we should have a sustained growth as well as, our margins are kind of intact. All these issues are being faced.
Show 25 more questions
Question
Lakshmi Narayanan Yeah. My question is that, you see, w e manufacture in India, if I'm right, and then we sell in the U.S. Now, given that every second year or third year, there has been some geopolitical issue or logistics issues, is it something the management can think of where you can identify another sourcing location? Where you can do something with your instead of making in India and then selling in the U.S.? Is it possible at all, or is it something which you want to explore at some point in time?
Answer, beni prasad
Beni Prasad Rauka I think if you really look at from the fermentation side, we will always continue to do it in India. Alternate sourcing, because it’s again, a 100% subsidiary company, we always see that we have to work on if there are any kind of alternate source. How we can also equally become competitive in the process by improving our productivity, by spending more on research. At least we don't have to look at any other source in that sense, and we can grow in India as well as in the U.S. and U.S., if you want to invest, there will be lot of money that will be required to invest in those kind of the capabilities.
Question
Lakshmi Narayanan Got it. But in case we are unable to grow, we’ll be losing some clients. Because the clients would be looking for raw materials, and this we don't provide, would it not be a challenge for you? Because if you're looking at a growth and for some reason, you're unable to ship, your end clients would then look for an alternate source, correct? Page 7 of 19 Beni Prasad Rauka I think that every business has lot of many challenges.
Answer, beni prasad
As we are into business, we have to address all these challenges. That's what we have been doing. Yes, when you have several challenges, you have to really work very hard to see that how you can sustain, and you can have a sustainable growth in the process. At the same time, you make good money.
Question
Zaki Nasser Sir, I think it's a decent set of numbers in difficult times. We had projected yearly growth of 13-15% over the next three to five years, sir. Do you think we can close this year at least 12% plus, sir, in the balance three quarters?
Answer, mukund kabra
Mukund Kabra As of now, we feel yes. Even this quarter, we lost around INR 10 crores because of the sales reversal, which will come in the next quarter. As of now, we think we should be able to grow in double digits.
Answer, beni prasad
Beni Prasad Rauka If you add the incremental reversal. Sorry, okay. Go ahead.
Question
Zaki Nasser Sir you please complete.
Answer, beni prasad
Beni Prasad Rauka I was just telling, as Mukund has mentioned, this particular quarter, we have incremental sales reversal. That means if we add INR 10 crores in INR 190 crores, so at least we added INR 200 crores in this quarter, which is roughly 8% kind of the growth. As we progress, we are confident that we shall be able to achieve the kind of growth numbers which we have shared with you in past.
Question
Zaki Nasser What about the cost trajectory, sir? Because I think most of our imports, including energy, it was at inflated levels this quarter. Do you think these costs have come under control from the Q2 onwards, sir?
Answer, beni prasad
Beni Prasad Rauka Yes. Because that definitely improve because of operational effici ency.
Question
Zaki Nasser If I may just ask a last question, sir. We are going in for a buyback of approximately INR 1.4 crore shares. I see that we have an ESOP pending conversions of around INR 2.5 crore shares. Is that right figure, sir? Have I got it right?
Answer, beni prasad
Beni Prasad Rauka No, sir. I don't know crores, where did you get these numbers.
Question
Okay. The ESOP says INR 25 lakh, correct? Pending conversion?
Answer, beni prasad
Beni Prasad Rauka Yeah. ESOP scheme was for 25 lakhs, but so far, we have granted, I think, in two different tranches, 11 lakhs shares only. Those shares will also vest over a period of five years. Still, there's a lot of time left.
Question
Umang Shah Hi, sir. Good afternoon. Am I audible?
Answer, beni prasad
Beni Prasad Rauka Yeah, please. I think some disturbance is there, but then I think we will have to bear with that, and we'll try to see what best we can do. Okay. Go ahead.
Question
Umang Shah Thank you. Not a problem. Yes, sure, sir. Sir, the first question that I had was, can you mention about your change in U.S. strategy and focusing on brand? Some quarters that you had mentioned that your customers have your name on their product, which helps them sell their product better. Now, when you say that you want to move more from a B2B to a B2C business, is that understanding correct? Or would you want to be in a B2B business but focus on the brand? If yes, then how will that work?
Answer, beni prasad
Beni Prasad Rauka I think business will not change. The only thing, even in B2B, when you say ingredient, there you sometimes say very specific that this is what is my ingredient. When you put a label, use this particular name as the ingredient.
Question
Umang Shah Okay. How will this expected to help us in our business?
Answer, beni prasad
Beni Prasad Rauka Then it becomes sticky business, no, in that sense. Once the label is with your name, then it becomes a kind of a sticky business.
Question
Umang Shah Understood. Sir, if you could break the Human Nutrition business between India and international, that would be great.
Answer, beni prasad
Beni Prasad Rauka I think I've given the numbers, but I will repeat for you. India business this quarter was INR 580 million as compared to INR 699 in Q4 of FY26 and INR 659 in Q1 of FY26. International sales was INR 559 million as compared to INR 582 and INR 562 million. Page 9 of 19 Umang Shah Okay.
Question
Understood. Thank you so much for repeating. Sir, just last one question. In terms of the competitive intensity that we had in terms of our largest product, has it gone away for good? Or is it still continuing? In terms of pricing, if last year, the pricing was 100 at this time, in Q1, what would be the pricing right now?
Answer, beni prasad
Beni Prasad Rauka Pricing is better in this particular quarter because we have increased some prices. It's better in that sense. Realization is better than Q4 and Q1 of last year.
Question
Umang Shah Can you quantify it roughly in range?
Answer, beni prasad
Beni Prasad Rauka I think that's what we were saying, that when we discussed in the past also, few things we would not like to discuss on the concall on, please.
Question
Umang Shah Not a problem. Sir, any view on biocatalysis segment?
Answer, beni prasad
Beni Prasad Rauka Biocatalysis number INR 45 million during this quarter as compared to INR 44 million in the last quarter of Q4.
Question
Umang Shah Right. We were planning to get into intermediate business, so I think one year back to grow this biocatalysis piece, but then we decided not to go for that. Now, how do we plan to grow this segment? It's considered to be one of the high-growth segments, right?
Answer, mukund kabra
Mukund Kabra It's still the high-growth segment for us. This year, we expect in the second half, good growth should come from this area.
Question
Ravi Purohit Hi. Thanks for the opportunity. Can you just explain me to what we mentioned about INR 10 crore sales reversal? This is basically sales return or sales? Is it like sales which have got canceled or sales which have not been booked? Or how does this entire cycle work? Page 10 of 19 Mukund Kabra Ravi, it's the sale in the transit, which is not reached to the customer.
Answer, mukund kabra
The material is already booked, but lot of, like, export shipment, it really didn't reach to the customer.
Question
Ravi Purohit Sorry, please finish, Rauka ji.
Answer, beni prasad
Beni Prasad Rauka I was saying that revenue recognition happened when the risk and reward is transferred to the customer. It was on a ship. It is not delivered to the customer, so you cannot recognize that as your revenue.
Answer, mukund kabra
Mukund Kabra Every quarter, we have a reversal, but this time it was -- Beni Prasad Rauka Incremental by 10. Mukund Kabra -- incremental by INR 10 crore. Yeah. The impact is more but by INR 10 crore.
Question
Ravi Purohit Okay. Sir, if you could kind of share some thoughts on, how are we kind of looking at scaling up products which we have outside of serratiopeptidase. Serratiopeptidase has been one very large product for us. Our dependence on it doing well is disproportionately higher, right, in any given year. If that product does well, the company's overall growth looks better. If that kind of drops off significantly, the growth kind of tapers off. Can you just share, what are the opportunities? Where are we kind of seeing newer products coming out of? Or if you could just throw some light on this.
Answer, mukund kabra
Mukund Kabra Ravi, we are working on very different, different industries. We are growing very well in the food areas. We are working on protein solubilization, all of those other areas. I don't want to name the product, but those are going to be also the potential product. We are working in all the other areas, and we'll see how it grows.
Question
Shreyans Gathani Hi, good afternoon, I had a question on the U. S. business. Although you mentioned that it's been flat, the currency depreciation has been enough, like rupee terms, it is flat. We're definitely seeing, I would assume, some volume declines there. I'm trying to understand what like, are we not having the right product, or what is going on? Some clarity on what the strategy is going forward. Rauka ji, you did mention about the branding, but I would think that the existing business is declining. Just trying to understand what is declining over there, what is not working out? Just some color on that.
Answer, beni prasad
Beni Prasad Rauka Currency decline, if you really talk about the USD, is about 4% decline. I mean, rupee has depreciated by 4% on QoQ basis. On YoY basis, it is declined by, I think, 10% depreciation.
Question
Shreyans Gathani Okay. Because I'm talking, like, over a period of time, we have lost business , right? Not just this quarter is what I'm mentioning.
Answer, beni prasad
Beni Prasad Rauka I think we have explained you that we are expecting 8-10% of growth in our U.S. business. That is what I think I already mentioned to you. The reason why there's a steady numbers in U.S., I think that also I explained you because of geopolitical issues. Then, again, as explained to you, we are working on several branding. All this is taking its time. As we progress, we will get more clarity, and I think we expect that we shall be having a better growth in the coming quarters. I think by the end of the year, it should be about 8% or so.
Question
Abhishek Kamdar I understand that EBITDA margins were softer this quarter on account of higher energy costs. For the rest of the year, do we expect to recover this to our historical levels? Or do we feel that it's still going to be subdued?
Answer, beni prasad
Beni Prasad Rauka Yes. We expect that it shall come back to the normal level of about 30% of EBITDA.
Question
I'll try to go slowly. I was asking if you could give us some examples of new products that we have introduced in the last few years, which are now contributing to our top line. Reason being, in the past decade or so, our growth has been pretty muted even after doing so many acquisitions. I mean, the growth is not really coming through. Hence, what I'm requesting, if you could help us understand what kind of products we've introduced in the last couple of years, and what products are we likely to introduce in the coming couple of years?
Answer, mukund kabra
Mukund Kabra See, I couldn't hear you clearly, but I will explain what I understand a little bit from your question. We don't track product to product sales. That's the first thing. I won't be able to give you the exact number, what is the revenue coming from the last two, three years product as of now? Your second question probably is, how many products we are under the working. We are always working on the new molecules, there are always 15-20 molecules under the pipeline, and few of them are always coming every quarter. That's how it works.
Question
Ketan Chheda Okay. And another question is on the margins. Now , if we see the last 10-11 years, our margins used to be in the 40s, and now it has dropped to 30s, and we are expecting to remain at that level. Now, is there a possibility that our margins could go up, and the reasons could be that you are introducing or coming up with better solutions and products for customers, which must be in the development of R&D right now, is there a possibility?
Answer, mukund kabra
Mukund Kabra See, R&D always helps in increasing the margins. But as of now, we will just like to continue that we will be having a 30-32% of EBITDA margin, and that is what we are saying. In R&D, we'll increase our pace to increase the productivity as well.
Question
Umang Shah Thank you, sir. My questions are answered.
Answer, beni prasad
Beni Prasad Rauka One gentleman asked about the inventory and working capital days. Inventory, 30th June 2026, was about INR 190 crores. We had a receivable of about INR 131 crores. Payables were about INR 41 crores. INR 280 crores was roughly invested in the working capital. In terms of number of days, generally our working capital cycle is about 125-138 days.
Question
Nikhil Upadhyay Yes. The only context which I brought in was, see, our business is not as such a very variable kind of a business. Because as I understand, once we've given a product or we are part of a chemistry or a process, that product or process will continue until unless we lose a customer. To that extent, then this kind of a variability should not be there. Once a base is set, that base should be set, and then we build the business over it. I'm trying to understand. Is that the right understanding, or is this not the proper way?
Answer, mukund kabra
Mukund Kabra Nikhil ji, you are right. Generally, like 70-80%, customers are always constant. 20-30% is changing in our business, and that is right. But at the same time, I would say that QoQ, you cannot just go on and say that last quarter it was this. What happened? Sometimes, you get some quick sales as well, and sometimes you don't get. That's all what it is.
Questions about this call
- When was the Advanced Enzyme Technologies Q1 FY27 earnings call transcript filed?
- Advanced Enzyme Technologies filed the transcript with the exchange on 18 Aug 2026. This page is built from that transcript.
- What does this page list?
- 28 statements from the transcript across 5 topics, 25 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 35 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.